I
IMMUNOVANT INC
NASDAQ: IMVT (Immunovant, Inc.)
Last update: 2 hours ago27.12
-0.02 (-0.09%)
| Previous Close | 27.15 |
| Open | 27.23 |
| Volume | 902,063 |
| Avg. Volume (3M) | 1,430,198 |
| Market Cap | 5,519,792,640 |
| Price / Book | 6.05 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2026 |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunovant, Inc. | Bullish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2025 | 11,526,971 |
| Armistice Capital, Llc | 31 Dec 2025 | 5,747,155 |
| Rtw Investments, Lp | 31 Dec 2025 | 3,177,850 |
| Two Seas Capital Lp | 31 Dec 2025 | 2,866,962 |
| Alpine Global Management, Llc | 31 Dec 2025 | 2,626,692 |
| Adar1 Capital Management, Llc | 31 Dec 2025 | 2,480,968 |
| Perceptive Advisors Llc | 31 Dec 2025 | 1,994,890 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 44.00 (Guggenheim, 62.24%) | Buy |
| Median | 39.50 (45.65%) | |
| Low | 35.00 (HC Wainwright & Co., 29.06%) | Buy |
| Average | 39.50 (45.65%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 27.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 35.00 (29.06%) | Buy | 26.68 |
| Guggenheim | 09 Feb 2026 | 44.00 (62.24%) | Buy | 27.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GIRAO TIAGO | - | 28.91 | -25,760 | -744,722 |
| STOUT JAY S | - | 28.91 | -2,754 | -79,618 |
| Aggregate Net Quantity | -28,514 | |||
| Aggregate Net Value ($) | -824,340 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 28.91 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STOUT JAY S | Officer | 23 Apr 2026 | Sell (-) | 2,754 | 28.91 | 79,618 |
| GIRAO TIAGO | Officer | 23 Apr 2026 | Sell (-) | 25,760 | 28.91 | 744,722 |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |